Development of a Novel Nanoemulsion Formulation to Improve Intestinal Absorption of Cannabidiol
Medical Cannabis and Cannabinoids · 04.04.2019 · 2 (1) · 35-42
DOI: 10.1159/000497361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Cannabis and Cannabinoids, online erschienen am 04.04.2019. Verfasst von Yukako Nakano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Therapeutics, Division of Pharmacokinetics and Pharmacodynamics, Showa University, Tokyo, Japan. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cannabidiol (CBD) is highly lipophilic, and its oral bioavailability is known to be very low in humans. In this study, we developed a novel nanoemulsion preparation of CBD (CBD-NE) to improve the poor solubility and absorption of CBD. The pharmacokinetic profiles of CBD in rats were evaluated after oral administrations of CBD oil and CBD-NE, and the effect of bile secretion on CBD absorption was also evaluated.
Methods
The CBD-NE formulation developed in this study consisted of vitamin E acetate, ethanol, Tween-20, and distilled water (1.7/3.8/70/24.5, w/w%). A CBD oil formulation (CBD oil, control) 100 mg/kg or CBD-NE 50 mg/kg was orally administered to rats, and the blood samples were collected over time. Moreover, the CBD oil or CBD-NE was orally administered to bile-fistulated rats, and the pharmacokinetic profiles of CBD were also evaluated. CBD concentrations in plasma were measured using LC-MS/MS.
Results
The particle size of CBD-NE was 35.3 ± 11.8 nm. Mean Tmax of CBD-NE was shortened significantly by the factor of 3 (from 8.00 to 2.40 h, p < 0.001) and AUC0–∞/dose increased by 65% (from 0.272 ± 0.045 to 0.448 ± 0.087 h L/kg) compared with CBD oil. AUC0–∞/dose and Cmax/dose after oral administration of CBD oil were significantly reduced by the factor of 27 and 23 (p < 0.05 and p < 0.01), respectively, in bile-fistulated rats compared with the untreated rats. In contrast, all pharmacokinetic parameters after oral administration of CBD-NE were not significantly different between the untreated and bile-fistulated rats. Therefore, these results demonstrated that conventional CBD oil formulation but not CBD-NE requires bile-mediated micelle formation.
Conclusions
The novel NE formulation developed in this study successfully improved the absorption of CBD regardless of bile secretion. The newly developed oral CBD-NE preparation could be useful to achieve a more stable and quicker onset of action by CBD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Toxicology and Therapeutics, Division of Pharmacokinetics and Pharmacodynamics, Showa University, Tokyo, Japan.
- Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Zitieren
APA
Nakano, Y., Tajima, M., Sugiyama, E., Sato, V. H., & Sato, H. (2019). Development of a Novel Nanoemulsion Formulation to Improve Intestinal Absorption of Cannabidiol. Medical Cannabis and Cannabinoids, 2(1), 35-42. https://doi.org/10.1159/000497361
Vancouver
Nakano Y, Tajima M, Sugiyama E, Sato VH, Sato H. Development of a Novel Nanoemulsion Formulation to Improve Intestinal Absorption of Cannabidiol. Medical Cannabis and Cannabinoids. 2019;2(1):35-42. doi:10.1159/000497361
BibTeX
@article{Nakano2019,
author = {Nakano, Yukako and Tajima, Masataka and Sugiyama, Erika and Sato, Vilasinee Hirunpanich and Sato, Hitoshi},
title = {Development of a Novel Nanoemulsion Formulation to Improve Intestinal Absorption of Cannabidiol},
journal = {Medical Cannabis and Cannabinoids},
year = {2019},
volume = {2},
number = {1},
pages = {35--42},
doi = {10.1159/000497361}
}
EUVIMED